Company profile for Altamira Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We at Auris Medical are dedicated to developing novel pharmaceutical products for the treatment of inner ear disorders and central nervous system disorders. We are focusing on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201). These programs have gone through two Phase 1 trials and will move into proof-of-concept s...
We at Auris Medical are dedicated to developing novel pharmaceutical products for the treatment of inner ear disorders and central nervous system disorders. We are focusing on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201). These programs have gone through two Phase 1 trials and will move into proof-of-concept studies in 2019. In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Bermuda
Address
Address
Clarendon House 2 Church Street Hamilton HM 11
Telephone
Telephone
+41 61 201 13 50
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-11-20/altamira-therapeutics-announces-certification-of-bentrio-nasal-spray-under-medical-device-regulation

PHARMIWEB
20 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-03/altamira-therapeutics-announces-successful-nanoparticle-based-delivery-of-dna-molecules

PHARMIWEB
03 Nov 2025

https://www.pharmiweb.com/press-release/2025-08-29/altamira-therapeutics-provides-business-update-and-first-half-2025-financial-results

PHARMAWEB
29 Aug 2025

https://www.pharmiweb.com/press-release/2025-08-26/altamira-therapeutics-to-host-first-half-2025-financial-results-and-business-update-call-on-august-2

PHARMAWEB
26 Aug 2025

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/altamira-therapeutics-announces-allowance-of-japanese-patent-applicat-1048826

ACCESSWIRE
15 Jul 2025

https://www.globenewswire.com/news-release/2025/05/27/3088689/0/en/Altamira-Therapeutics-Announces-Collaboration-on-Circular-RNA-Delivery.html

GLOBENEWSWIRE
27 May 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty